Injury blow for Barcelona as Spain midfielder to miss PSG Champions League clash

Injury blow for Barcelona as Spain midfielder to miss PSG Champions League clash

Barcelona have confirmed that Spain midfielder Fermín Lopez will be sidelined for around three weeks after picking up an injury during Sunday’s 3-0 La Liga victory over Getafe, Afrosport reports.

The 22-year-old left the Estadio Johan Cruyff in tears, clutching his groin, before being consoled by manager Hansi Flick

Subsequent tests at the club’s headquarters on Monday revealed an iliopsoas muscle injury in his left leg, ruling him out until mid-October.

The setback comes at a critical moment for Barcelona, who face reigning European champions Paris Saint-Germain in the Champions League on 1 October.

Lopez, who rejected an offer from Chelsea in the summer to fight for a first-team place at Camp Nou, had made a strong start to the season with two goals in five appearances across all competitions.

His absence deepens Barcelona’s mounting injury concerns. Lamine Yamal’s return remains dependent on his daily recovery, while Alejandro Balde, Marc-Andre ter Stegen and Gavi are also unavailable.

For Gavi, the 21-year-old is set to undergo an arthroscopic surgery to deal with a meniscus problem in his knee. Barcelona revealed that the operation will take place on Tuesday, and a date for his returned was not announced.

“Gavi underwent intense sporting stress tests after finishing his conservation course of treatment for the radial injury to the internal meniscus in his right knee,” a statement said.

“The conclusion is that in order to guarantee the best possible recovery and return to competitive action, this Tuesday Gavi will undergo an arthroscopic examination by Dr. Joan Carles Monllau, under the supervision of the club’s staff.”

Flick’s side now head into a congested schedule before the international break: away to Real Oviedo on Thursday, at home to Real Sociedad three days later, and then the high-stakes clash with PSG.

Facebook
Twitter
LinkedIn
Leave a Reply

Your email address will not be published. Required fields are marked *

Top Stories